Table 3.

Characteristics of ¹⁷⁷Lu-DOTATATE and competitor radiolabeled SSAs and somatostatin antagonists.

Compound	Peptide	Radionuclide	Unique Characteristics
177Lu-DOTATATE	Octreotate	177Lu	Compared to 90Y-DOTATOC, it has greater tumor uptake and a reduced risk of toxicity due to the medium energy B-emitting character of 177Lu. This agent has randomized phase III data while no other radiolabeled SRA has such data yet.
90Y-DOTATOC	Octreotide	90Y	90Y is a high energy B-emitter with a potential ability to be more effective than 177Lu for larger metastases. This was one of the first radiolabeled SSAs to be trialed in humans.
111In-DOTATOC	Octreotide	111In	111In emits γ rays and conversion electrons. It was the initial radiolabeled SSA trialed in humans therapeutically after initially being used at lower doses for diagnostic purposes.
177Lu-DOTA-EB-TATE	Octreotate	177Lu	The Evans Blue modification of the somatostatin analog enables reversible binding to albumin which increases the circulating half-life of the radiolabeled SSA and increases its tumor exposure.
177Lu-OPS201	OPS201	177Lu	OPS201 is a somatostatin receptor 2 antagonist (which is not internalized) and may result in increased DNA damage than 177Lu-DOTATATE.

Abbreviations: ¹⁷⁷Lu, lutetium-177; ⁹⁰Y, yttrium-90; SSA, ¹¹¹In, indium-111; SSA, somatostatin receptor agonist